Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session

1919 - Molecular imaging with 18F-Fluoroestradiol (18F-FES) to assess intra-patient heterogeneity in metastatic breast cancer (MBC): a European TRANSCAN program.


11 Sep 2017


Poster display session


Cancers in Adolescents and Young Adults (AYA);  Staging Procedures (not Imaging);  Translational Research;  Breast Cancer


Alessandra Gennari


Annals of Oncology (2017) 28 (suppl_5): v22-v42. 10.1093/annonc/mdx363


A. Gennari1, E. Brain2, O. Nanni3, E. Muñoz Couselo4, N. Harbeck5, R. Geiss2, A. Rocca6, J. Cortés7, T. Degenhardt8, A. Piccardo9, J. Albérini2, F. Matteucci10, A. Decensi1, D.S. Corradengo1, D. Andreis3, D. Marra1, G. Gebhart11, C. Brambati12, D. Amadori13, P. Bruzzi14

Author affiliations

  • 1 Oncology, Ospedali Galliera, 16128 - Genova/IT
  • 2 Oncology, Hôpital René Huguenin - Institut Curie, 92210 - St. Cloud/FR
  • 3 Biostatistics, IRCCS IRST, 47014 - Meldola (FC)/IT
  • 4 Oncology, Vall d'Hebron University Hospital, 08035 - Barcelona/ES
  • 5 Breast Center, Ludwig Maximilians University - Grosshadern, 81377 - Munich/DE
  • 6 Oncology, IRCCS IRST, 47014 - Meldola (FC)/IT
  • 7 Clinical Research Department, Vall d'Hebron Institute of Oncology (VHIO), 08035 - Barcelona/ES
  • 8 Oncology, Ludwig Maximilians University - Grosshadern, 81377 - Munich/DE
  • 9 Nuclear Medicine, Ospedali Galliera, 16128 - Genova/IT
  • 10 Nuclear Medicine, IRCCS IRST, 47014 - Meldola (FC)/IT
  • 11 Nuclear Medicine, Institute Jules Bordet, 1000 - Brussels/BE
  • 12 Clinical Research, Advanced Accelerator Applications, 01630 - SAINT GENIS POUILLY/FR
  • 13 Department Of Medical Oncology, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola/IT
  • 14 Clinical Epidemiology, Ospedale San Martino, 16132 - Genoa/IT


Abstract 1919


Endocrine responsiveness in Estrogen Receptor positive (ER+) MBC is based on the level of ER expression on the primary tumor and/or metastatic lesion. In this study, nested in the ET-FES JTC 2011 TRANSCAN project, we used molecular imaging with 18F-FES to explore intra-patient heterogeneity in ER expression at different metastatic sites and to identify patients who are not likely to benefit from ET.


ER+ patients at first relapse underwent at baseline a 18F-FES PET/CT plus a 18F-fluoro-2-deoxy-D-glucose (FDG) PET/CT. Patients were classified into 4 18F-FES/FDG subgroups based on the proportion of FDG avid metastatic tumor load with high 18F-FES uptake (Gebhart Ann Oncol 2016). Subgroup A was considered positive (100% of concordance); subgroups B and C were considered partially positive or partially negative, with different degrees of 18F-FES uptake; subgroup D was considered negative (100% of discordance). Patients with global SUV ≥2 received first line ET while those with SUV


So far, 80 patients have been enrolled in the ET-FES trial and 79 are included in the present analysis. At baseline evaluation, 53 patien4ts (67.1%) were classified as 18F-FDG/18F-FES positive (A); 16 patients (20.3%) showed some degree of intra-patient heterogeneity (11 group B and 5 group C); 10 patients (12.6%) were classified as D with all lesions being 18F-FES negative. In the 64 patients with a response evaluation available at time of analysis, 26 have shown progression. ET was administered in 40 patients in group A and in 24 patients in groups B + C + D. The use of ET alone in partially positive (B) or partially negative (C) or negative (D) patients was associated with a 79% absolute increase in the risk of progression (HR 1.79, p 0.2) compared to patients in group A.


Pretreatment ER biomarker imaging at different metastatic sites with 18F-FES PET/CT indicate the presence of a significant intra-patient heterogeneity in MBC and represents a promising tool to select patients who are unlikely to benefit from ET alone.

Clinical trial identification

EUDRACT 2013-000-287-29

Legal entity responsible for the study

E.O. Ospedali Galliera, Genoa, Italy




C. Brambati: Employer Advanced Accelerator Applications. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.